INTRODUCTION AND OBJECTIVES: Up to 20% of renal transplant recipients have anatomical or functional bladder or the outlet abnormalities which are either pre-existing or evident before the transplant or are latent and manifest during the post-transplant follow up. This study focussed on overview, bladder management and transplant outcome in patients with latent bladder or the outlet abnormalities which manifested after the transplant in recipient.
METHODS: A prospective observational study of patients who underwent renal transplant with latent bladder abnormalities which manifested with a variable spectrum of LUTS or the graft dysfunction was done from January 2012 to July 2017. We identified and noted the etiopathogenesis, post-transplant interventions required; bladder related complications and long term graft function.
RESULTS: Of the 720 renal transplants performed during this period, 160 patients (22.2%) (Mean Age 28 AE 8.5 Years) had new onset LUTS or latent bladder abnormalities which manifested within 1 month of renal transplant. The study cohort was stratified in two groups on the basis of type and duration of intervention required; Group 1 ( 6 months of nonsurgical treatment, n[ 112), group 2 (> 6 months of non surgical treatment and or requiring surgical treatment, n[48). Most common presenting symptom was dysuria (n[110) followed by increased frequency (n[104), poor stream (n[72) or both (n[60). Etiologies included overactive bladder OAB (n[76), transient voiding dysfunction (n [52), functional bladder neck obstruction (n[10), dysfunctional voiding (n[4), diabetic cystopathy (n[5) and BPH or related cystopathy (n[8), unidentified aetiology (n[5). Group 1 was managed with short-term medical management with anticholinergics or alpha blockers or both and improved within six months. Whereas group 2 were managed with continuous pharmacotherapy for > 6 months or CIC and urotherapy (n[39), bladder neck incision (n[5) or TURP/TUIP (n[4). Recurrent UTI occurred in 15 (13%) Vs 18 (38%), patients in group 1 Vs group 2 (p[0.01) in the post-transplant period. Graft survival was satisfactory at 1 year and were comparable between the groups (95% Vs 91%, p[0.47).
CONCLUSIONS: About one in five transplant recipients manifests new onset LUTS and are detected to have either bladder dysfunction or outlet abnormalities in the early post transplant period. Majority of them improve on short-term nonsurgical therapy. However those requiring long-term nonsurgical or surgical treatment are more likely to develop frequent urinary tract infections. Overall outcome of renal transplant in terms of graft function was satisfactory following optimal bladder management.
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MP76-06 GENETIC PREDISPOSITION WITH REGARDS TO THE ROLE OF MMPS IN ALLOGRAFT REJECTIONS FOLLOWING RENAL TRANSPLANTATION
Aneesh Srivastava*, Narayan Prasad, Mansi Bhatt, Lucknow, India INTRODUCTION AND OBJECTIVES: Allograft rejection remains to be one of the crucial impediments in successful renal transplantation. Matrix metalloproteinases (MMPs) play an important role in immune-mediated tissue destruction of the allograft by allowing influx of leucocytes and mononuclear cells into the graft and it appears that, the study of the role of MMPs in transplant rejection process may also lead to novel approaches in the therapy of rejection processes. The present study was, therefore, undertaken to investigate the association of functional polymorphisms in MMP-1 (-1607 1G/2G), (-519 A/G); MMP-3(5356 A/G), (1161 A/G) and MMP-9 (1721G/C), (Q279R A/G), (R668Q G/A) genes with risk of allograft rejection in renal transplant recipients of North India.
METHODS: One hundred fifty live related renal transplant donors and recipients were genotyped for MMP-1, MMP-3 and MMP-9 gene polymorphisms by polymerase chain reactionerestriction fragment length polymorphism methodology. Only sixty eight recipient samples were categorized into 57 non-rejecters and 11 rejecters and were analyzed further.
RESULTS: The analysis showed that genotype frequencies of MMP1 (-1607 1G/2G) 
